Potential treatment

[키워드] 1.26 95% CI 95% confidence interval Admission aggravation Alpha Anakinra analyses Analysis anti-inflammatory agent anti-inflammatory agents Asia assessment associations Azithromycin benefit Cardiac complications cardiac safety risk cardiac safety risks cardiac-impaired population cardiac-impaired populations carried categories category Causality certainty clinical clinical benefit clinical benefits Clinical outcome clinical settings clinical trial ClinicalTrials clinician Cochrane Library collected Combination Comparative controlled trials convalescent plasma coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids Course COVID-19 COVID-19 disease COVID-19 disease course COVID-19 treatments CRD42020186527 Critically ill Critically ill patient critically ill patients daclatasvir dataset determine development disease course drug effective Efficacy and safety eligibility criteria eligible Europe evaluate Evidence evidence of fatal cardiac complication fatal cardiac complications Google Scholar help heterogeneous High-dose Hospitalization hospitalized COVID-19 patients Hydroxychloroquine ICU Immunoglobulin information intensive care intensive care unit interferon interferon-alpha Intravenous immunoglobulin investigated itolizumab Ivermectin IVIG Level management mechanical ventilation medRxiv Meta-analysis Middle East mild patients moderate moderate to severe moderate/high evidence certainty Mortality mortality rate mortality rates Network meta-analysis NMA non-ICU non-ICU setting noncardiac serious adverse events North America Numerous observational studies observational study Odds ratio outcome Patient patients hospitalized pharmacological agent pharmacological intervention pharmacological interventions pharmacological management plasma Policy populations Potential treatment potential treatments progression PROSPERO provide QT prolongation QT prolongation incidence Randomized controlled trial Randomized controlled trials randomized trial randomized trials RCT RCTs recommendations reduce reduce COVID-19 aggravation reduce mortality rate reduced reflected registry Remdesivir Research researcher Result risk risk of bia RoB RoB2 ROBINS-I framework searched self-limiting disease Serious Adverse Event Serious Adverse Events severe COVID-19 patient severe disease severe pneumonia shown significantly sofosbuvir sofosbuvir plus daclatasvir South America SSRN standard care Study protocol supported systematic review systematic synthesis Tocilizumab translated Treatment treatment regimen viral clearance rate vulnerable population WHO WHO International Clinical Trials Registry Platform
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis